THERAPEUTIC ANTI-BODY SERVICES TECHNOLOGIES (Q2035366): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item: Label in wikidata changed) |
||
label / en | label / en | ||
THERAPEUTIC ANTI-BODY SERVICES TECHNOLOGIES |
Revision as of 11:20, 17 March 2020
Project in Italy financed by DG Regio
Language | Label | Description | Also known as |
---|---|---|---|
English | THERAPEUTIC ANTI-BODY SERVICES TECHNOLOGIES |
Project in Italy financed by DG Regio |
Statements
188,379.49 Euro
0 references
376,758.97 Euro
0 references
50.000001327108414 percent
0 references
12 December 2016
0 references
6 July 2019
0 references
EXIRIS S.R.L.
0 references
GLI ANTICORPI SONO AGENTI TERAPEUTICI DI GRANDE SUCCESSO CHE VENGONO UTILIZZATI PER IL TRATTAMENTO DI MALATTIE ONCOLOGICHE, INFIAMMATORIE, AUTO IMMUNI E CARDIOVASCOLARI. IL NUMERO DI FARMACI BASATI SU ANTICORPI Ê IN CONTINUA CRESCITA (Italian)
0 references
Identifiers
F81B18000200007
0 references